Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
INDOCO REMEDIES TEVA PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
INDOCO REMEDIES Mar-23 |
TEVA PHARMA Dec-13 |
INDOCO REMEDIES/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 423 | 3,459 | - | |
Low | Rs | 308 | 3,005 | - | |
Sales per share (Unadj.) | Rs | 181.1 | 1,985.4 | - | |
Earnings per share (Unadj.) | Rs | 15.4 | 124.0 | - | |
Cash flow per share (Unadj.) | Rs | 23.1 | 284.5 | - | |
Dividends per share (Unadj.) | Rs | 2.25 | 108.57 | - | |
Avg Dividend yield | % | 0.6 | 3.4 | 18.3% | |
Book value per share (Unadj.) | Rs | 111.5 | 2,205.4 | - | |
Shares outstanding (eoy) | m | 92.15 | 848.00 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 2.0 | 1.6 | 124.0% | |
Avg P/E ratio | x | 23.7 | 26.1 | 90.9% | |
P/CF ratio (eoy) | x | 15.8 | 11.4 | 139.3% | |
Price / Book Value ratio | x | 3.3 | 1.5 | 223.6% | |
Dividend payout | % | 14.6 | 87.5 | 16.7% | |
Avg Mkt Cap | Rs m | 33,683 | 2,741,007 | 1.2% | |
No. of employees | `000 | NA | 44.9 | 0.0% | |
Total wages/salary | Rs m | 3,226 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 37,459.7 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 2,340.1 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 16,686 | 1,683,624 | 1.0% | |
Other income | Rs m | 24 | 0 | - | |
Total revenues | Rs m | 16,710 | 1,683,624 | 1.0% | |
Gross profit | Rs m | 2,860 | 461,061 | 0.6% | |
Depreciation | Rs m | 706 | 136,089 | 0.5% | |
Interest | Rs m | 250 | 33,069 | 0.8% | |
Profit before tax | Rs m | 1,928 | 291,903 | 0.7% | |
Minority Interest | Rs m | 0 | 1,326 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -191,619 | -0.0% | |
Tax | Rs m | 505 | -3,564 | -14.2% | |
Profit after tax | Rs m | 1,423 | 105,175 | 1.4% | |
Gross profit margin | % | 17.1 | 27.4 | 62.6% | |
Effective tax rate | % | 26.2 | -1.2 | -2,147.2% | |
Net profit margin | % | 8.5 | 6.2 | 136.5% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 8,082 | 1,137,114 | 0.7% | |
Current liabilities | Rs m | 4,245 | 991,659 | 0.4% | |
Net working cap to sales | % | 23.0 | 8.6 | 266.1% | |
Current ratio | x | 1.9 | 1.1 | 166.0% | |
Inventory Days | Days | 25 | 91 | 27.6% | |
Debtors Days | Days | 768 | 96 | 800.4% | |
Net fixed assets | Rs m | 9,055 | 549,909 | 1.6% | |
Share capital | Rs m | 184 | 4,144 | 4.4% | |
Net worth | Rs m | 10,276 | 1,870,187 | 0.5% | |
Long term debt | Rs m | 1,435 | 860,875 | 0.2% | |
Total assets | Rs m | 17,137 | 3,847,621 | 0.4% | |
Interest coverage | x | 8.7 | 9.8 | 88.6% | |
Debt to equity ratio | x | 0.1 | 0.5 | 30.3% | |
Sales to assets ratio | x | 1.0 | 0.4 | 222.5% | |
Return on assets | % | 9.8 | 3.6 | 271.7% | |
Return on equity | % | 13.8 | 5.6 | 246.2% | |
Return on capital | % | 18.6 | 4.9 | 377.2% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 1,788 | 268,283 | 0.7% | |
From Investments | Rs m | -2,082 | -95,063 | 2.2% | |
From Financial Activity | Rs m | 228 | -321,823 | -0.1% | |
Net Cashflow | Rs m | -65 | -148,604 | 0.0% |
Compare INDOCO REMEDIES With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US)
Compare INDOCO REMEDIES With: BLUE JET HEALTHCARE WYETH SANJIVANI PA AMRUTANJAN HEALTHCARE DIVIS LABORATORIES
Asian shares slipped before a Bank of Japan policy decision where authorities are likely to bring an end to the world's last negative rates regime.